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Abstract
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory
follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus
bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t
[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed
for MRD at mid-induction (MI), end of induction (EOI), and every 6–24 months post-EOI/discontinuation by real-time
quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving
Benda alone (p = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving
Benda alone (p = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI,
0.19–0.56, p < 0.0001) and overall survival (HR, 0.39, 95% CI, 0.19–0.78, p = 0.008) vs. MRD-positive patients, and
maintained their MRD-negative status for longer if they received G maintenance than if they did not. These results suggest
that the addition of G to Benda-based treatment during induction can signiﬁcantly contribute to the speed and depth of
response, and G maintenance in MRD-negative patients potentially delays lymphoma regrowth.
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Relapsed disease remains a signiﬁcant challenge in the
treatment of indolent non-Hodgkin lymphoma (NHL) [1].
Early identiﬁcation of patients who are at high risk of
relapse may be important for treatment optimization. In
addition to imaging techniques, assessment of minimal
residual disease (MRD) has emerged as potentially important for the detection of residual tumor cells, and thus the
evaluation of treatment efﬁcacy and long-term prognosis in
this patient population [2–9]. Achieving MRD response has
been associated with improved outcome in patients with
follicular lymphoma (FL), independent of clinical remission
status, and pretreatment patient characteristics [8]. However, previous studies on the use of MRD assessment in
NHL have predominantly been in ﬁrst-line patient populations, and data on MRD in patients with relapsed/refractory
disease are limited.
Obinutuzumab (G) is a glycoengineered, type II antiCD20 antibody with enhanced biological activity when
compared with type I antibodies, such as rituximab [10, 11].
G is approved for treatment of chronic lymphocytic
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leukemia (CLL; ﬁrst-line in combination with chlorambucil) and FL (ﬁrst-line in combination with chemotherapy, followed by G maintenance; relapsed/
rituximab-refractory disease in combination with bendamustine [Benda], followed by G maintenance) [12, 13].
GADOLIN (NCT01059630) was an international, openlabel, multicenter, and randomized phase 3 trial evaluating
the efﬁcacy and safety of G plus Benda induction followed
by G maintenance (G-Benda arm) vs. Benda induction
alone (Benda arm) in patients with rituximab-refractory
indolent NHL (iNHL; predominantly FL) [14]. The study
showed a statistically signiﬁcant improvement in
progression-free survival (PFS) and overall survival (OS) in
the G-Benda arm compared with the Benda arm [14–16].
No difference was observed between treatment arms in
overall or complete response (CR) rates at the end of
induction (EOI) [14–16].
Using updated efﬁcacy data with a median follow up of
31.8 months, this paper reports the results of a preplanned
MRD assessment in patients with FL enrolled in GADOLIN.
The main objectives of the analysis were: (1) to evaluate the
depth and time course of the MRD response to G-Benda or
Benda by assessing MRD during induction (mid-induction;
MI) and at EOI, and throughout G maintenance (G-Benda
arm) or follow up (Benda arm); and (2) to assess the association between EOI MRD status and PFS and OS.

Methods
Data sharing statement
Qualiﬁed researchers may request access to individual
patient level data through the clinical study data request
platform (www.clinicalstudydatarequest.com). Further
details on Roche’s criteria for eligible studies are available
here (https://clinicalstudydatarequest.com/Study-Sponsors/
Study-Sponsors-Roche.aspx). For further details on
Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study
documents, see here (https://www.roche.com/research_and_
development/who_we_are_how_we_work/clinical_trials/
our_commitment_to_data_sharing.htm).

Study design and patients
The GADOLIN study design and patient population has
been described in full elsewhere [14]. In brief, patients aged
18 years or older with rituximab-refractory, histologically
documented CD20 + iNHL were randomly assigned (1:1)
to six cycles of G (cycle 1: 1000 mg on days 1, 8, and 15;
cycles 2–8: 1000 mg on day 1) plus Benda (cycles 1–6:
90 mg/m2 on days 1 and 2; G-Benda arm) or Benda alone
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(cycles 1–6: 120 mg/m2 on days 1 and 2; Benda arm).
Randomization was stratiﬁed according to iNHL subtype
(FL or other), refractory type (rituximab monotherapy or
rituximab plus chemotherapy), number of previous therapies (two or more, or less than two), and geographic region.
Patients in the G-Benda arm with no evidence of progression at EOI (i.e., those with CR, partial response [PR], or
stable disease [SD]) received G maintenance (1000 mg)
every 2 months for 2 years. The study was conducted in
accordance with the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good
Clinical Practice. The protocol was approved by the ethics
committees of the participating centers. Written consent for
MRD assessment was provided by patients.

Deﬁnition of MRD status and analysis time points
MRD status was evaluated at screening in peripheral blood
(PB) and bone marrow (BM), at MI (cycle 4, day 1) in PB,
at EOI in PB and BM, and at 6-monthly intervals during
maintenance (G-Benda arm) or follow up (Benda arm) in
PB up to 24 months post-EOI or treatment discontinuation.
MRD status of a sample was deﬁned as positive (MRDpositive) if one of the real-time quantitative polymerase
chain reaction (RQ-PCR) and subsequent nested PCR
assays produced a speciﬁc PCR signal according to the
applied criteria and quality checks. MRD status of a sample
was deﬁned as negative (MRD-negative; also sometimes
referred to as MRD undetectable) if RQ-PCR and subsequent nested PCR produced no speciﬁc PCR signal in a
sample with at least 104 control gene copies (albumin
control gene). MRD status at a time point was deﬁned as
positive if at least one of all evaluable samples (PB or BM)
was positive by RQ-PCR conﬁrmed by nested PCR. In
patients for whom both PB and BM samples were available,
the higher MRD value was used for calculation of quantitative MRD values and assessment. Concordance of PB and
BM results was assessed, i.e., results where both samples
were negative (undetectable) and where both were positive
(including positive but unquantiﬁable).
Assessments during maintenance/follow up were conducted at 6, 12, and 18 months after EOI, and at the ﬁnal
(∼28 days after the 24-month visit) or early termination/
discontinuation visit. Only patients without disease progression at EOI were assessed for MRD during maintenance/follow up. Samples collected at or subsequent to
documented clinical relapse were not included in the statistical analysis.

MRD assessment
MRD assessment was based on detection of clonal markers
in PB and BM aspirate samples at screening in patients with
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FL; patients with other types of iNHL were not included in
this analysis. Samples were analyzed centrally in a reference
laboratory in Kiel, Germany.
The diagnostic PB and BM samples were screened
initially by consensus PCR (modiﬁed according to van
Dongen et al.) [17] to detect a t(14;18) translocation and/or
clonal immunoglobulin heavy chain (IGH) or light chain
(IG kappa [IGK]) rearrangement suitable for MRD assessment. In patients with a detectable clonal marker, sequencing of clonal IG rearrangements was done for the design of
allele-speciﬁc oligonucleotides (ASO) for RQ-PCR. All
assays were designed with a sensitivity of ≤10−5, but were
accepted for analysis when a sensitivity of ≤10−4 was
reached. In case of two available markers, the most sensitive
marker was chosen for MRD analysis. MRD quantiﬁcation
was performed as described previously [18, 19]. For
determining the quantitative MRD levels, target copy
numbers were related to the number of target copies of
tenfold serial dilutions of cell lines or plasmids used for
quantiﬁcation of the respective rearrangement. In patients
for whom no marker could be detected in PB or BM,
identiﬁcation of the clonal rearrangement from formalinﬁxed, parafﬁn-embedded tissue (FFPET; lymph nodes
[LNs]) was attempted.
Standards for quantiﬁcation by RQ-PCR were obtained
by different approaches. For patients with a t(14;18) translocation (major breakpoint region [MBR], 3′MBR, minor
cluster region [MCR] and 5′MCR), either cell lines
(DOHH2, SC1, K231) or two cloned plasmids bearing all
known t(14;18) breakpoint sites of MBR, 3′MBR, MCR, 5′
MCR cloned into a pEN08H vector were used to establish
standard curves for quantiﬁcation. A forward primer and
probes were placed in chromosome 18 in combination with
a reverse primer placed in the consensus JH region on
chromosome 14. This was designed in such a way that RQPCR products did not exceed a maximum of 200 base pairs
in size, to prevent differences in ampliﬁcation efﬁciency.
The plasmids had been standardized for sensitivity and
reproducibility in multiple quality control rounds of the
EuroMRD consortium.
For patients with a clonal IG rearrangement, the speciﬁc
IGH or IGK rearrangement was cloned, and ASO primers were designed for ASO RQ-PCR.
Cloning was performed using the TOPO TA cloning Kit
(Thermo Fisher Scientiﬁc, MA, USA). Quantiﬁcation by
plasmid standards was conducted using a modiﬁed protocol
according to Gimenez et al. [20]. MRD levels were given as
a fraction of number of FL cells per total number of
mononuclear BM or PB cells analyzed per PCR assay. All
RQ-PCR data were evaluated according to EuroMRD
consortium guidelines [19] to establish sensitivity and
quantitative range for all patients and to measure tumor load
in each sample. For conﬁrmatory reasons, all samples
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analyzed by RQ-PCR were additionally analyzed by nested
PCR adapted from the published literature [21, 22].

Statistical analysis
MRD status at MI, EOI, and during maintenance or follow
up was tabulated against treatment arm, and the association
was tested using Fisher’s Exact test. The association of PFS
and OS with MRD status at EOI was determined using a
landmark analysis measuring survival time from the date of
the EOI MRD sample (to avoid ascertainment bias) in
patients without progression at EOI. Differences between
patient subgroups were visualized using Kaplan–Meier
plots and analyzed with Cox proportional hazards models.
The data cut off for the current analysis was April 1, 2016.
Statistical analyses were conducted using SAS v9.2.

Results
MRD marker identiﬁcation
From April 15, 2010 to January 24, 2015, 335 patients with
FL were enrolled in the GADOLIN study. From the 319
patients with PB and/or BM samples available at baseline
(baseline-evaluable population), 554 diagnostic samples
were screened (313 PB, 189 BM, 52 LNs). Clonal markers
were detected in 228/319 (71%) patients. In 22 of these
patients, clones were detected in LN FFPET. Two of these
were subsequently detected in BM and seven in PB; the
remaining 13 could not be detected in either PB or BM and
so no MRD analysis was performed in follow-up samples.
A detectable MBR, 3′MBR or MCR t(14,18) translocation was identiﬁed in 144/228 (63%) patients, with this
being the only marker identiﬁed in 63 patients. A clonal IG
rearrangement was detected in 165/228 (72%), with this
being the only marker identiﬁed in 84 patients. Both markers were present in 81/228 (36%) patients (Table 1).
In total, 166/319 patients (52%) had an RQ-PCR assay
fulﬁlling the sensitivity criteria (≤10−4), 90% of those
achieving a sensitivity of 10−5. In the majority of cases, a t
(14;18) translocation-based RQ-PCR assay was used (62%
MBR/3′MBR breakpoint, 8% MCR/5′MCR breakpoint)
and in 30%, IGH/IGK rearrangements served as an MRD
target.

Table 1 Frequency of BCL2 and Ig-based MRD markers for all
patients
Patients with
molecular marker

t(14;18) only IgH only Both marker
positive

228

63

84

81
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Fig. 1 MRD analysis
population. The asterisk
indicates the PB sample
available at MI for assessment of
MRD response kinetics; the
dagger indicates the PB and/or
BM sample available at EOI for
MRD response assessment
(MRD-evaluable population);
the hash symbol indicates the
patients with ≥1 MRD sample at
EOI (in PB/BM) and/or during
maintenance and follow up
(PB). BM bone marrow, EOI
end of induction, FL follicular
lymphoma, MI mid-induction,
MRD minimal residual disease,
PB peripheral blood, and RQPCR real-time quantitative
polymerase chain reaction

Overall, 145 patients were evaluable for MRD response
assessment at any of the timepoints: MI (n = 88), EOI (n =
118), or had at least one MRD assessment during maintenance and follow up (n = 138). (MRD-response evaluable
population, Fig. 1).
A clonal marker was detected more frequently in patients
with a higher incidence of Ann Arbor stage IV disease at
diagnosis, higher Follicular Lymphoma International Prognostic Index (FLIPI) score at initial diagnosis, and more
frequent BM and extranodal involvement at baseline
(Table 2), with a slightly higher proportion of patients in the
G-Benda treatment arm displaying these worse prognostic
factors. Overall, this resulted in poorer PFS in patients with
a detectable marker (Supplementary Fig. S1) compared with
those without a detectable clonal marker, reﬂecting a higher
tumor load in this patient population. Time from last
treatment to randomization was similar in the two groups
(median 3.7 vs. 3.9 months in patients with and without a
detectable clonal marker, respectively). Other demographic
parameters, including age and sex, were well balanced
between the populations, and when compared with the
overall GADOLIN population [14].

MRD status and kinetics
At study entry, 202/313 (65%) PB and 105/189 (55%) BM
samples had a detectable clonal marker. Quantitative
assessment of circulating lymphoma cells (CLC) revealed a
median level of 0.5% lymphoma cells in PB at screening. In
BM, a median inﬁltration of 2% FL cells was determined.
Low-level CLC or BM inﬁltration below the limit of
quantiﬁcation (<10−4) was present in 33/164 (20%) PB
samples and 21/94 (22%) BM samples.

For 91 patients who had RQ-PCR results for both PB and
BM samples at screening, RQ-PCR values for the two
samples correlated, and there was a high level of concordance between the PB and BM results for these patients
(r2 = 0.71) (Supplementary Fig. S2). Overall, 78 of 91 paired
diagnostic samples were concordantly positive or positive
below the limit of quantiﬁcation and six were concordantly
negative. Discordant results occurred in only seven paired
samples; in ﬁve of these, the positive samples demonstrated
low-level positivity below the quantitative range. Of the two
discordant cases, one was positive in BM and negative in PB,
the other one positive in PB and negative in BM.
MRD negativity in PB occurred early during induction
and was more rapid and frequent in the G-Benda treatment
arm; 41/52 (78.8%) patients in the G-Benda arm were
MRD-negative at MI vs. 17/36 (47.2%) patients in the
Benda arm (p = 0.0029; Fig. 2a). At EOI, more patients had
MRD responses in PB and/or BM, with 54 of 63 (85.7%)
patients in the G-Benda arm vs. 30 of 55 (54.5%) patients in
the Benda arm (p = 0.0002; Fig. 2b). During maintenance
in the G-Benda arm and follow up in the Benda arm,
missing samples and increasing discontinuation rates
impacted the number of MRD evaluable patients. Nevertheless, the majority of MRD-evaluable patients (55/66;
83%) in the G-Benda arm were MRD-negative compared
with only 9 of 39 (23%) patients in the Benda arm (who
received no maintenance treatment) in the 6–12-month
sampling window (Fig. 3). Of note, over the 2-year post
induction period, the rate of discontinuation was much
higher in the Benda arm compared with the G-Benda arm
(89 vs. 49% after more than 23 months), and a much lower
proportion of patients remained MRD-negative (3% in the
Benda arm vs. 28% in the in the G-Benda arm).
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Table 2 Demographics and baseline disease characteristics for patients
with or without a detectable clonal marker, and all baseline-evaluable
patients
No marker
detected

Median age, years
(range)

(n = 91)

Marker
Total
detected, with/
without RQPCR assay
(n = 228)
(n = 319)

63 (34–87)

63 (34–87)

63 (34–87)

Male, n (%)

49 (53.8)

129 (57)

178 (55.8)

ECOG PS, n (%)

(n = 91)

(n = 227)

(n = 318)

0–1

89 (97.8)

214 (94)

303 (95.3)

2

2 (2.2)

13 (6)

15 (4.7)

I

11 (12.9)

7 (3)

18 (6.0)

II

13 (15.3)

22 (10)

35 (11.6)

III

30 (35.3)

45 (21)

75 (24.8)

IV

31 (36.5)

143 (66)

174 (57.6)

Ann Arbor stage,a n (%)

Unknown

6

11

17

(n = 91)

(n = 227)

(n = 318)

Low (0–1)

35 (40.7)

41 (19)

76 (24.9)

Intermediate (2)

26 (30.2)

78 (36)

104 (34.1)

FLIPI, 1 adverse
factors risk category,a
n (%)

High (≥3)

25 (29.1)

100 (46)

125 (41.0)

Unknown

5

8

13

(n = 87)

(n = 218)

(n = 305)

Bone marrow
involvement,a n (%)
Positive

9 (10.3)

83 (38)

92 (30.2)

Negative

74 (85.1)

127 (58)

201 (65.9)

Insufﬁcient sample

3 (3.4)

5 (2)

8 (2.6)

Other

1 (1.1)

3 (1)

4 (1.3)

Extranodal involvement,a n (%)
Yes

37 (46.3)

120 (55)

157 (52.9)

No

43 (53.8)

97 (45)

140 (47.1)

Unknown

11

11

Time from initial diagnosis to randomization (months)

22
a

Mean (SD)

50.6 (41.3)

51.9 (53.9)

51.5 (50.6)

Median (range)

39.8
(3.8–215.6)

34.6
(3.1–384.8)

36.2
(3.1–384.8)

Time from last regimen to randomization (months)a
Mean (SD)

5.8 (6.03)

8.0 (13.3)

7.4 (11.7)

Median (range)

3.7
(0.7–37.5)

3.9
(0.7–128.4)

3.8
(0.7–128.4)

ECOG Eastern Cooperative Oncology Group, FLIPI Follicular
Lymphoma International Prognostic Index, PS performance status,
RQ-PCR real-time quantitative polymerase chain reaction, SD standard
deviation
a

Differences ≥10% between groups are in bold

Association between MRD status and outcome
Of the patients with a CR or PR from both treatment arms,
those who were MRD-negative in PB and/or BM at EOI
had longer subsequent PFS (HR, 0.33; 95% CI, 0.19–0.56)
and OS (HR, 0.39; 95% CI, 0.19–0.78) compared with
those who were MRD-positive (Fig. 4a, b). MRD-positive
patients in the G-Benda and Benda arms had similar unfavorable median PFS values, i.e., 3.3 months (95% CI,
2.20–8.18) and 3.3 months (1.74–not reached), respectively
(Fig. 4c). For MRD-negative patients, those in the Benda
arm had a shorter PFS (median, 8.54 months; 95% CI,
6.54–18.10) than those in the G-Benda arm (median,
35.71 months; 95% CI, 16.16–not reached). The HRs for
PFS in each arm (MRD-negative relative to MRD-positive)
were 0.29 (95% CI, 0.11–0.76) for G-Benda and 0.32 (95%
CI, 0.17–0.60) for Benda. For OS, the HRs were 0.37 (95%
CI, 0.01–1.38) and 0.39 (95% CI, 0.17–0.89), respectively.
MRD-positive patients in the Benda arm tended to relapse
quickly, as did MRD-positive patients in the G-Benda
group, four of whom progressed within the ﬁrst 6 months
after EOI. However, it should be noted that patients in the
G-Benda arm received G maintenance after EOI, while
those in the Benda arm did not.
Achievement of MRD negativity at EOI was associated
with clinical remission (CR or PR) (Table 3); however,
there were ﬁve patients who had a CR but were MRDpositive at EOI. In three of these patients, the CR was shortlasting, with disease progression recorded 2–5 months later.
In the other two patients, whose CR responses lasted for at
least two further years, only low-level MRD below the limit
of quantiﬁcation had been detectable in BM at EOI.
The independent value of MRD response for both PFS
and OS after the EOI was explored in a multivariate model,
which included treatment and baseline assessments for
bulky disease, extranodal involvement, FLIPI status, the
number of previous lines of therapy, double refractory status, and sex (Supplementary Table S1). The model results
are summarized using a likelihood ratio test, assessing the
additional inﬂuence of each variable on the overall model,
given all the other variables. For PFS, MRD status at EOI
was found to be strongly predictive, along with treatment
arm and FLIPI status. For the OS model, the same variables
had the greatest predictive value, although to a lesser extent
than for PFS. The HR for MRD status at EOI, adjusted for
treatment and baseline factors, was 0.214 for PFS and 0.317
for OS.

Discussion
We prospectively analyzed MRD in the context of the
GADOLIN trial to determine response to G-Benda and
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Fig. 2 MRD status at MI in PB
(a) and at EOI in PB and/or BM
(b). Benda bendamustine, BM
bone marrow, EOI end of
induction, G obinutuzumab, MI
mid-induction, MRD minimal
residual disease, and PB
peripheral blood

Fig. 3 MRD status in blood at the end of induction, and throughout G
maintenance or follow up in the Benda arm (a) and in the G-Benda
arm (b). Benda bendamustine, BM bone marrow, EOI end of

induction, G obinutuzumab, MRD minimal residual disease, and PB
peripheral blood
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Fig. 4 PFS (a) and OS (b) by MRD status at EOI in PB and/or BM,
and PFS (c) and OS (d) by MRD status at EOI in PB and/or BM and
by treatment arm in patients without progression at EOI. Benda

C. Pott et al.

bendamustine, BM bone marrow, EOI end of induction, G obinutuzumab, MRD minimal residual disease, PB peripheral blood, and PFS
progression-free survival

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in. . .
Table 3 Correlation of clinical
response with MRD
status at EOI

CR (n = 23)

PR (n = 76)

SD (n = 3)

529
PD (n = 9)

Missing

Total

MRD-positive, n (%)

5 (21.7)

16 (21.1)

2 (66.7)

7 (77.8)

4

34

MRD-negative, n (%)

18 (78.3)

60 (78.9)

1 (33.3)

2 (22.2)

3

84

CR complete response, EOI end of induction, MRD minimal residual disease, PD progressive disease, PR
partial response, SD stable disease

Benda treatment arms at the molecular level, and to investigate whether MRD status after induction therapy at relapse
has an impact on prognosis.
There was an imbalance in disease characteristics at
baseline between patients with and without detectable clonal markers, with greater prevalence of poor prognostic
factors in the patients with detectable clonal markers, which
was reﬂected by a shorter PFS. Consequently, the population analyzed for MRD response was not fully representative of the complete GADOLIN study sample.
In the current study, a signiﬁcantly greater proportion of
patients receiving G-Benda achieved MRD negativity at
EOI compared with patients receiving Benda alone.
Remarkably, the majority of evaluable patients in the GBenda arm had already achieved MRD negativity by MI,
suggesting rapid response kinetics, and demonstrating that
the combination of G with Benda signiﬁcantly contributes
to the depth and speed of response during induction treatment. MRD response at EOI was also associated with
achievement of clinical PR/CR at EOI (Table 3). These
ﬁndings suggest that MRD assessment is not only a sensitive tool for response assessment, but also allows early
identiﬁcation of clinical responders.
Given that patients in the GADOLIN trials were previously treated with (chemo)immunotherapy (median two
prior treatments), and were in part rituximab-refractory, it is
remarkable that the rate of MRD negativity achieved at EOI
in the G-Benda arm (85.7% of the MRD-evaluable population) is comparable with that reported in a study of
patients with FL treated ﬁrst-line with rituximab plus chemotherapy (85%) [23]. However, in ﬁrst-line treatment of
patients with FL and high tumor burden, immunochemotherapy with G (GALLIUM trial) achieved even higher
rates of MRD negativity at EOI, i.e., 92% in patients
receiving G-based therapy and 85% in those on rituximabbased therapy [24].
Patients who were MRD-positive at EOI had a poor
prognosis, irrespective of treatment arm, while an MRDnegative status at EOI was signiﬁcantly associated with
improved PFS and OS, regardless of treatment. However,
patients in the G-Benda arm achieving clinical and MRD
response and receiving G-maintenance appear to have the
most favorable outcome. In contrast, patients achieving
clinical CR but no MRD response after G-Benda relapsed
quickly within the ﬁrst 6 months after EOI despite G-

maintenance, demonstrating that MRD response is critical
and predictive for disease control by maintenance treatment.
Maintenance treatment with G appeared to sustain the
MRD response in patients who achieved MRD-negative
status in the G-Benda arm. In contrast, MRD-negative
patients in the Benda arm who did not receive maintenance
were found to relapse earlier and convert back to MRD
positivity. This seems somehow contradictory to data in
ﬁrst-line treatment of FL patients, where long-term prognosis is excellent when patients achieve MRD response
after induction, independent of treatment [25].
Beside the fact that it is difﬁcult to compare data on ﬁrstline and relapse treatment, it can be assumed that the residual lymphoma load below the limit of detection of RQPCR is probably higher in the less effective Benda arm
compared with the antibody combination treatment, resulting in a faster lymphoma regrowth kinetics. However, more
importantly, MRD-negative G-Benda patients received
ongoing active maintenance treatment, which contrasts with
the MRD-negative Benda cohort. Considering the concept
of MRD response as a surrogate marker for sensitivity to
treatment, it is expected that treatment intervention with an
efﬁcient maintenance therapy would affect outcome.
Although these results should be interpreted with some
caution due to the low patient numbers in the Benda arm
during follow up, our observation supports the use of G
maintenance in sustaining MRD negativity and repressing
regrowth of the lymphoma clone. Maintaining MRD
negativity throughout rituximab maintenance has previously
been associated with improved PFS [22].
In the primary GADOLIN analysis, no substantial differences were observed in computed tomography (CT)based CR rates (11% G-Benda vs. 12% Benda) or overall
response rates (69% G-Benda, 63% Benda) at staging after
induction, although PFS and OS were improved in the GBenda arm relative to the Benda arm [14]. However, this
was clearly the case when applying MRD for response
assessment; a signiﬁcant difference in MRD response rates
was detectable between the two treatment arms. The association between MRD negativity and improved PFS and OS
in the current study may suggest that MRD assessment is a
more sensitive response measure than standard CT-based
response assessment [15, 24], although this is limited to the
patient population with a detectable circulating clonal
marker at baseline.
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In patients with relapsed/refractory FL, a CT-based
response assessment of PR may be based on the ﬁnding of
residual LN enlargement. However, this enlargement may
not reﬂect residual disease, but rather residual ﬁbrotic tissue
[26] or slowly responding disease, providing a possible
explanation for why a number of patients in the current
study were assessed as having a PR, despite being MRDnegative at EOI (N = 60).
A recent study of MRD assessment in patients with CLL,
demonstrated that the MRD status assessed in PB in
responding patients according to the 2008 International
Workshop on Chronic Lymphocytic Leukemia criteria has
greater predictive value than the prognostic impact of
clinical complete or partial remission and allows for
improved PFS prediction in patients who achieve a PR or
CR [27].
Furthermore, a similar analysis in patients with FL
showed that PFS did not differ signiﬁcantly between MRDnegative patients with either a CR or a PR [8]. Consequently, these results suggest that MRD-negativity may
have better prognostic value for long-term outcome than
clinical response.
The current study demonstrated a lower frequency of
marker detection in PB and BM at study entry compared
with ﬁrst-line FL treatment in the GALLIUM trial [24]. This
may be due to recent prior rituximab and/or chemotherapy
treatment (median 4 months) in the GADOLIN population,
and consequent B-cell depletion. Median time from last
treatment to randomization was slightly longer in the clonal
marker-detectable vs. the nondetectable population,
although it should be noted that this difference was not
signiﬁcant. As the median level of CLC is only 0.5% in PB,
a greater number of screening BM samples with a higher
level of FL cell inﬁltration might have improved the rate of
marker detection. For future clinical trials with prospective
MRD assessment, systematic analysis of DNA extracted
from FFPET (LN) could be of value to identify an MRD
marker in a higher proportion of patients. However, of the
22 patients in our study whose marker was not identiﬁed
from peripheral samples but was identiﬁed in LN tissue,
subsequent analysis of PB and/or BM samples at screening
by allele speciﬁc RQ-PCR detected lymphoma cells in only
nine patients. This suggests that in some of these patients,
relapse is mainly located in the involved LN rather than in
other compartments. Here, like in diffuse large B-cell
lymphoma, the analysis of circulating tumor DNA as a
fragment of cell-free DNA might be much more informative
for MRD assessment than tracing CLC by genomic DNA
analysis [28].
Positron emission tomography (PET) scanning was not
used in the GADOLIN trial, as information on its utility in
iNHL was scarce at the time of study design;[14] however,
PET is now recommended for NHL disease staging and
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assessment of response to treatment due to its superior
accuracy over standard CT [15]. Therefore, it may be useful
to combine both PET and MRD in response assessment, as
the techniques address different compartments for residual
lymphoma cells. A combined PET and MRD response after
induction might be also used as endpoint in clinical trials to
reduce treatment in patients with excellent prognosis. A
recent analysis of 41 patients with FL who were treated with
rituximab plus chemotherapy as part of the FOLL05 trial
did not ﬁnd a strong correlation between PET and MRD,
but suggested that they could be used as complementary
techniques at the end of therapy [29].
In the same way that metabolic response is used to
stratify patients for radiation treatment in Hodgkin’s lymphoma and aggressive lymphomas, MRD response could be
used to stratify patients for different maintenance strategies,
including experimental treatment with novel drugs in MRDpositive patients.
In conclusion, the current analysis of MRD in patients
with rituximab-refractory FL enrolled in the GADOLIN
trial found improved MRD negativity rates in patients
receiving G-Benda vs. Benda alone. MRD negativity at EOI
was associated with improved PFS and OS, with this being
more pronounced in patients who received maintenance
therapy. The ﬁndings support the notion that MRD status at
EOI is a sensitive marker of the efﬁcacy of G-based treatment in the setting of relapsed/refractory FL. In addition,
the ﬁndings of the current study, and of others such as the
GALLIUM study, support the use of MRD assessment as
part of routine clinical practice; however, further research is
needed to determine the appropriate management strategy in
patients with MRD positivity.
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